{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "Toulouse University Hospital, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France",
    "FIG Therapeutics, Valhalla, NY, USA",
    "Pneumology and Thoracic Oncology, CHU de Lille, Lille, France",
    "Université Paris Saclay, Gustave Roussy, Villejuif, France",
    "Universite Paris-Saclay, Gif-sur-Yvette, France",
    "Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors Team, INSERM, Université Paris Cité, Sorbonne Université, Paris, France",
    "Université Paris Cité, AP-HP, Hôpital Bichat, Paris, France, France",
    "3 CIT, Ligue Nationale Contre Le Cancer, Paris, France",
    "Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique - Hôpitaux de Marseille, Marseille, France",
    "1Pathology, Centre Léon Bérard, LYON, France",
    "Biostatistics, French Cooperative Thoracic Intergroup, Paris, France",
    "Gustave Roussy Cancer Campus, Villejuif, France",
    "Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France, France",
    "Gustave Roussy, Villejuif, France, France",
    "Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France, France"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Julien Mazières"
    },
    {
      "affs": [
        1
      ],
      "name": "Aurélien Marabelle"
    },
    {
      "affs": [
        2
      ],
      "name": "Arnaud Scherpereel"
    },
    {
      "affs": [
        3
      ],
      "name": "Nathalie Chaput"
    },
    {
      "affs": [
        4
      ],
      "name": "David Planchard"
    },
    {
      "affs": [
        5
      ],
      "name": "Didier Jean"
    },
    {
      "affs": [
        6
      ],
      "name": "Gérard Zalcman"
    },
    {
      "affs": [
        7
      ],
      "name": "Yuna Blum"
    },
    {
      "affs": [
        8
      ],
      "name": "Laurent Greillier"
    },
    {
      "affs": [
        9
      ],
      "name": "Sylvie Lantuejoul"
    },
    {
      "affs": [
        10
      ],
      "name": "Alexandra Langlais"
    },
    {
      "affs": [
        11
      ],
      "name": "Matthieu Roulleaux Dugage"
    },
    {
      "affs": [
        12
      ],
      "name": "Guillaume Tosato"
    },
    {
      "affs": [
        13
      ],
      "name": "Jean Jouniaux"
    },
    {
      "affs": [
        14
      ],
      "name": "Elodie Amour"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/58tjz21g4qg7j.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.0036",
  "fulltext_url": null,
  "id": "58tjz21g4qg7j",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.0036",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2740|Occupational and environmental lung diseases"
    ]
  ],
  "openalex": "W7225136821",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_2/A38.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/58tjz21g4qg7j.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T14:21:04Z",
      "native_id": "361b718ed5bf40b7a24fca65b5c5b4d8",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.0036"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "journal-openalex:2403|Immunotherapy and Immune Responses",
      "subfield": "immunology"
    },
    {
      "field": "medicine",
      "origin": "lcc:RC254-282",
      "subfield": "oncology"
    }
  ],
  "title": "36 Baseline systemic immune profiles predict prognosis and differential benefit from ipilimumab intensification in relapsed mesothelioma (Bio-IFCT-1501 MAPS2 trial)",
  "title_text": "36 Baseline systemic immune profiles predict prognosis and differential benefit from ipilimumab intensification in relapsed mesothelioma (Bio-IFCT-1501 MAPS2 trial)",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:17Z",
  "url": "https://research.draconitic.com/paper/58tjz21g4qg7j",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}